Creative Planning’s InMed Pharmaceuticals INM Stock Holding History

Creative Planning’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4	Closed	-$5K	–	2379
2022 Q2	$5K	Hold	4	–	–	﹤0.01%	2227
2022 Q1	$10K	Hold	4	–	–	﹤0.01%	2193
2021 Q4	$14K	Hold	4	–	–	﹤0.01%	2048
2021 Q3	$19K	Hold	4	–	–	﹤0.01%	2049
2021 Q2	$34K	Hold	4	–	–	﹤0.01%	1966
2021 Q1	$36K	Hold	4	–	–	﹤0.01%	2391
2020 Q4	$36K	Buy	+4	New	+$32.5K	﹤0.01%	2131

Other funds holding INM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Creative Planning's INM Position: Q3 2022 in Review

Creative Planning sold out of InMed Pharmaceuticals (INM) in Q3 2022, closing a stake of 4 shares — an estimated $5K sold.

Creative Planning first reported a position in INM in Q4 2020 and held it in 7 quarters. The position peaked at $36K in Q1 2021. 9 funds tracked by Wall St. Rank hold INM as of Q3 2022.

Creative Planning reported no remaining InMed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Creative Planning sold 4 InMed Pharmaceuticals shares in Q3 2022, an estimated $5K.
Creative Planning first reported a position in InMed Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Creative Planning's InMed Pharmaceuticals position peaked at $36K in Q1 2021.
9 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q3 2022.

Based on Creative Planning's 13F filing for Q3 2022, filed 3 Nov 2022.